|
1
|
Davies L and Welch HG: Current thyroid
cancer trends in the United States. JAMA Otolaryngol Head Neck
Surg. 140:317–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sherman SI: Thyroid carcinoma. Lancet.
361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smallridge RC and Copland JA: Anaplastic
thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol
(R Coll Radiol). 22:486–497. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim TY, Kim KW, Jung TS, Kim JM, Kim SW,
Chung KW, Kim EY, Gong G, Oh YL, Cho SY, et al: Prognostic factors
for Korean patients with anaplastic thyroid carcinoma. Head Neck.
29:765–772. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pierie JP, Muzikansky A, Gaz RD, Faquin WC
and Ott MJ: The effect of surgery and radiotherapy on outcome of
anaplastic thyroid carcinoma. Ann Surg Oncol. 9:57–64. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smallridge RC, Ain KB, Asa SL, Bible KC,
Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal
MS, et al American Thyroid Association Anaplastic Thyroid Cancer
Guidelines Taskforce, : American Thyroid Association guidelines for
management of patients with anaplastic thyroid cancer. Thyroid.
22:1104–1139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Igney FH and Krammer PH: Death and
anti-death: Tumour resistance to apoptosis. Nat Rev Cancer.
2:277–288. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu B, Han M, Wen JK and Wang L:
Livin/ML-IAP as a new target for cancer treatment. Cancer Lett.
250:168–176. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sanna MG, da Silva Correia J, Ducrey O,
Lee J, Nomoto K, Schrantz N, Deveraux QL and Ulevitch RJ: IAP
suppression of apoptosis involves distinct mechanisms: The
TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol.
22:1754–1766. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Allen SM, Florell SR, Hanks AN, Alexander
A, Diedrich MJ, Altieri DC and Grossman D: Survivin expression in
mouse skin prevents papilloma regression and promotes
chemical-induced tumor progression. Cancer Res. 63:567–572.
2003.PubMed/NCBI
|
|
12
|
Wang L, Zhang Q, Liu B, Han M and Shan B:
Challenge and promise: Roles for Livin in progression and therapy
of cancer. Mol Cancer Ther. 7:3661–3669. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang H and Schimmer AD: Livin/melanoma
inhibitor of apoptosis protein as a potential therapeutic target
for the treatment of malignancy. Mol Cancer Ther. 6:24–30. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yan B: Research progress on Livin protein:
An inhibitor of apoptosis. Mol Cell Biochem. 357:39–45. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun JG, Liao RX, Zhang SX, Duan YZ, Zhuo
WL, Wang XX, Wang ZX, Li DZ and Chen ZT: Role of inhibitor of
apoptosis protein Livin in radiation resistance in nonsmall cell
lung cancer. Cancer Biother Radiopharm. 26:585–592. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoon TM, Kim SA, Lee DH, Lee JK, Park YL,
Lee KH, Chung IJ, Joo YE and Lim SC: Livin enhances chemoresistance
in head and neck squamous cell carcinoma. Oncol Rep. 37:3667–3673.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tanabe H, Yagihashi A, Tsuji N, Shijubo Y,
Abe S and Watanabe N: Expression of survivin mRNA and livin mRNA in
non-small-cell lung cancer. Lung Cancer. 46:299–304. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Augello C, Caruso L, Maggioni M, Donadon
M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C,
Roncalli M, et al: Inhibitors of apoptosis proteins (IAPs)
expression and their prognostic significance in hepatocellular
carcinoma. BMC Cancer. 9:1252009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gazzaniga P, Gradilone A, Giuliani L,
Gandini O, Silvestri I, Nofroni I, Saccani G, Frati L and Aglianò
AM: Expression and prognostic significance of LIVIN, SURVIVIN and
other apoptosis-related genes in the progression of superficial
bladder cancer. Ann Oncol. 14:85–90. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li CJ, Cong Y, Liu XZ, Zhou X, Shi X, Wu
SJ, Zhou GX and Lu M: Research progress on the livin gene and
osteosarcomas. Asian Pac J Cancer Prev. 15:8577–8579. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiang Y, Yao H, Wang S, Hong M, He J, Cao
S, Min H, Song E and Guo X: Prognostic value of Survivin and Livin
in nasopharyngeal carcinoma. Laryngoscope. 116:126–130. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun K, Liao Q, Chen Z, Chen T and Zhang J:
Expression of Livin and PlGF in human osteosarcoma is associated
with tumor progression and clinical outcome. Oncol Lett.
16:4953–4960. 2018.PubMed/NCBI
|
|
23
|
Wang R, Lin F, Wang X, Gao P, Dong K, Zou
AM, Cheng SY, Wei SH and Zhang HZ: Silencing Livin gene expression
to inhibit proliferation and enhance chemosensitivity in tumor
cells. Cancer Gene Ther. 15:402–412. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu S, Li X, Li Q, Liu H, Shi Y, Zhuo H,
Li C and Zhu H: Silencing Livin improved the sensitivity of colon
cancer cells to 5-fluorouracil by regulating crosstalk between
apoptosis and autophagy. Oncol Lett. 15:7707–7715. 2018.PubMed/NCBI
|
|
25
|
Miura K, Fujibuchi W, Ishida K, Naitoh T,
Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C, et al:
Inhibitor of apoptosis protein family as diagnostic markers and
therapeutic targets of colorectal cancer. Surg Today. 41:175–182.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jing C, Gao Z, Wang R, Yang Z, Shi B and
Hou P: Lenvatinib enhances the antitumor effects of paclitaxel in
anaplastic thyroid cancer. Am J Cancer Res. 7:903–912.
2017.PubMed/NCBI
|
|
28
|
Ogino H, Hanibuchi M, Kakiuchi S, Trung
VT, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, et
al: E7080 suppresses hematogenous multiple organ metastases of lung
cancer cells with nonmutated epidermal growth factor receptor. Mol
Cancer Ther. 10:1218–1228. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yoon TM, Kim SA, Park YL, Lee KH, Sung MW,
Lee JK, Lim SC, Chung IJ and Joo YE: Expression of the receptor
tyrosine kinase recepteur d'origine nantais and its association
with tumor progression in hypopharyngeal cancer. Head Neck.
35:1106–1113. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goffredo P, Thomas SM, Adam MA, Sosa JA
and Roman SA: Impact of timeliness of resection and thyroidectomy
margin status on survival for patients with anaplastic thyroid
cancer: An analysis of 335 cases. Ann Surg Oncol. 22:4166–4174.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baek SK, Lee MC, Hah JH, Ahn SH, Son YI,
Rho YS, Chung PS, Lee YS, Koo BS, Jung KY, et al: Role of surgery
in the management of anaplastic thyroid carcinoma: Korean
nationwide multicenter study of 329 patients with anaplastic
thyroid carcinoma, 2000 to 2012. Head Neck. 39:133–139. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pezzi TA, Mohamed AS, Sheu T, Blanchard P,
Sandulache VC, Lai SY, Cabanillas ME, Williams MD, Pezzi CM, Lu C,
et al: Radiation therapy dose is associated with improved survival
for unresected anaplastic thyroid carcinoma: Outcomes from the
National Cancer Data Base. Cancer. 123:1653–1661. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Haymart MR, Banerjee M, Yin H, Worden F
and Griggs JJ: Marginal treatment benefit in anaplastic thyroid
cancer. Cancer. 119:3133–3139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tiedje V, Stuschke M, Weber F, Dralle H,
Moss L and Führer D: Anaplastic thyroid carcinoma: Review of
treatment protocols. Endocr Relat Cancer. 25:R153–R161. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tohyama O, Matsui J, Kodama K, Hata-Sugi
N, Kimura T, Okamoto K, Minoshima Y, Iwata M and Funahashi Y:
Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor
that targets multiple receptor tyrosine kinases in preclinical
human thyroid cancer models. J Thyroid Res. 2014:6387472014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schlumberger M, Tahara M, Wirth LJ,
Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff
AO, et al: Lenvatinib versus placebo in radioiodine-refractory
thyroid cancer. N Engl J Med. 372:621–630. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oishi K, Takabatake D and Shibuya Y:
Efficacy of lenvatinib in a patient with anaplastic thyroid cancer.
Endocrinol Diabetes Metab Case Rep. 2017:16–0136. 2017.PubMed/NCBI
|
|
38
|
Koyama S, Miyake N, Fujiwara K, Morisaki
T, Fukuhara T, Kitano H and Takeuchi H: Lenvatinib for anaplastic
thyroid cancer and lenvatinib-induced thyroid dysfunction. Eur
Thyroid J. 7:139–144. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tahara M, Kiyota N, Yamazaki T, Chayahara
N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, et
al: Lenvatinib for Anaplastic Thyroid Cancer. Front Oncol.
7:252017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Deveraux QL and Reed JC: IAP family
proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kasof GM and Gomes BC: Livin, a novel
inhibitor of apoptosis protein family member. J Biol Chem.
276:3238–3246. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chung CY, Park YL, Kim N, Park HC, Park
HB, Myung DS, Kim JS, Cho SB, Lee WS and Joo YE: Expression and
prognostic significance of Livin in gastric cancer. Oncol Rep.
30:2520–2528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li F, Yin X, Luo X, Li HY, Su X, Wang XY,
Chen L, Zheng K and Ren GS: Livin promotes progression of breast
cancer through induction of epithelial-mesenchymal transition and
activation of AKT signaling. Cell Signal. 25:1413–1422. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin X, Li HR, Lin XF, Yu ME, Tu XW, Hua
ZD, Lin M, Xu NL, Han LL and Chen YS: Silencing of Livin inhibits
tumorigenesis and metastasis via VEGF and MMPs pathway in lung
cancer. Int J Oncol. 47:657–667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xi RC, Sheng YR, Chen WH, Sheng L, Gang
JJ, Tong Z, Shan Z, Ying GH, Dong LC and Chen YS: Expression of
survivin and livin predicts early recurrence in non-muscle invasive
bladder cancer. J Surg Oncol. 107:550–554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen YS, Li HR, Lin M, Chen G, Xie BS, Xu
NL and Lin LF: Livin abrogates apoptosis of SPC-A1 cell by
regulating JNKI signaling pathway. Mol Biol Rep. 37:2241–2247.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hoshi T, Watanabe Miyano S, Watanabe H,
Sonobe RM, Seki Y, Ohta E, Nomoto K, Matsui J and Funahashi Y:
Lenvatinib induces death of human hepatocellular carcinoma cells
harboring an activated FGF signaling pathway through inhibition of
FGFR-MAPK cascades. Biochem Biophys Res Commun. 513:1–7. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
El Ali Z, Grzymisławski M, Majewski P,
Baumann-Antczak A and Kosowicz J: Anti-livin antibodies: Novel
markers of malignant gastrointestinal cancers. Pol Arch Med Wewn.
120:26–29. 2010.PubMed/NCBI
|
|
49
|
Yagihashi A, Asanuma K, Tsuji N, Torigoe
T, Sato N, Hirata K and Watanabe N: Detection of anti-livin
antibody in gastrointestinal cancer patients. Clin Chem.
49:1206–1208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yagihashi A, Asanuma K, Kobayashi D, Tsuji
N, Shijubo Y, Abe S, Hirohashi Y, Torigoe T, Sato N and Watanabe N:
Detection of autoantibodies to livin and survivin in Sera from lung
cancer patients. Lung Cancer. 48:217–221. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yagihashi A, Ohmura T, Asanuma K,
Kobayashi D, Tsuji N, Torigoe T, Sato N, Hirata K and Watanabe N:
Detection of autoantibodies to survivin and livin in sera from
patients with breast cancer. Clin Chim Acta. 362:125–130. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang L, Xu Z, Chen X, Duan Y, Chen Z and
Sun J: Clinical benefits of Livin peptide-loaded DCs/CIKs combined
with chemotherapy in advanced non-small cell lung cancer. Am J
Cancer Res. 9:406–414. 2019.PubMed/NCBI
|
|
53
|
Yin L, Liu S, Li C, Ding S, Bi D, Niu Z,
Han L, Li W, Gao D, Liu Z, et al: CYLD downregulates Livin and
synergistically improves gemcitabine chemosensitivity and decreases
migratory/invasive potential in bladder cancer: The effect is
autophagy-associated. Tumour Biol. 37:12731–12742. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang Z, Liu S, Ding K, Ding S, Li C, Lu J,
Gao D, Zhang T and Bi D: Silencing Livin induces apoptotic and
autophagic cell death, increasing chemotherapeutic sensitivity to
cisplatin of renal carcinoma cells. Tumour Biol. 37:15133–15143.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liu Y, Guo Q, Zhang H, Li GH, Feng S, Yu
XZ, Kong LS, Zhao L and Jin F: Effect of siRNA-Livin on drug
resistance to chemotherapy in glioma U251 cells and
CD133+ stem cells. Exp Ther Med. 10:1317–1323. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhuang L, Shen LD, Li K, Yang RX, Zhang
QY, Chen Y, Gao CL, Dong C, Bi Q, Tao JN, et al: Inhibition of
livin expression suppresses cell proliferation and enhances
chemosensitivity to cisplatin in human lung adenocarcinoma cells.
Mol Med Rep. 12:547–552. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zou AM, Wang HF, Zhu WF, Wang FX and Shen
JJ: Effect of RNAi-mediated silencing of Livin gene on biological
properties of colon cancer cell line LoVo. Genet Mol Res.
13:3832–3841. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang TS, Ding QQ, Guo RH, Shen H, Sun J,
Lu KH, You SH, Ge HM, Shu YQ and Liu P: Expression of Livin in
gastric cancer and induction of apoptosis in SGC-7901 cells by
shRNA-mediated silencing of Livin gene. Biomed Pharmacother.
64:333–338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang X, Xu J, Ju S, Ni H, Zhu J and Wang
H: Livin gene plays a role in drug resistance of colon cancer
cells. Clin Biochem. 43:655–660. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Oh BY, Kim KH, Chung SS and Lee RA:
Silencing the livin gene enhances the cytotoxic effects of
anticancer drugs on colon cancer cells. Ann Surg Treat Res.
91:273–277. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yuan D, Liu L, Xu H and Gu D: The effects
on cell growth and chemosensitivity by livin RNAi in non-small cell
lung cancer. Mol Cell Biochem. 320:133–140. 2009. View Article : Google Scholar : PubMed/NCBI
|
